Yes — and it is costing eye care practices far more than they realize. Denials in ophthalmology billing have traditionally meant a hard rejection with a clear reason code.
But in 2025–2026, a more dangerous pattern has taken over: payers are processing claims at reduced rates — or silently bundling services — without issuing a formal denial at all.
These “hidden” revenue losses do not trigger your denial worklist. They quietly drain your collections month after month.
The Problem Has Quietly Changed
Not long ago, a denial was obvious. You received a Claim Adjustment Reason Code (CARC), your billing team identified the issue, and you either corrected or appealed. That workflow still exists — but it now misses a large and growing share of revenue loss.
According to CMS data, the Medicare denial rate across Part B claims hovers between 10% and 18% depending on specialty and provider type. However, that figure only captures hard rejections.
It does not capture claims processed at 60–80% of the contracted allowable because a payer’s automated system bundled a separate diagnostic service into the E/M visit — with no denial code issued.
Denials in ophthalmology billing are increasingly taking this silent form. A claim for CPT 92134 (OCT of the optic nerve) billed alongside 92012 (intermediate ophthalmological exam) may be auto-bundled by the payer’s claim-scrubbing logic — paid as a single combined unit at a lower fee rather than denied and returned for appeal.
Why Ophthalmology Is a High-Risk Specialty for Silent Underpayments
Eye care practices bill across two distinct insurance lanes — medical and vision — and that split alone creates complexity that most general RCM vendors do not fully navigate.
Add in high-cost intravitreal injections, 90-day global periods for cataract surgery, and the frequent mix of diagnostic imaging with clinical evaluation, and you have a specialty with multiple underpayment entry points.
Three specific triggers are responsible for the majority of silent revenue loss in 2026:
1. Modifier -25 on Same-Day Injection Visits
When a physician evaluates a patient and also administers an intravitreal injection of bevacizumab (J9035) or aflibercept (J0178), the E/M visit requires modifier -25 to be separately reimbursed. CMS guidelines allow this under the Medicare Claims Processing Manual (Chapter 12).
However, several Medicare Advantage and commercial payers are now auto-reducing or auto-bundling the E/M without a denial — simply by applying a lower allowed amount. Practices that do not run a monthly payer allowable analysis will never catch this.
2. JZ Modifier Compliance
Effective January 1, 2023, CMS mandated the JZ modifier on single-dose drug claims with zero waste. Any ophthalmology practice billing intravitreal agents — some of which exceed $2,000 per vial — without correct JZ or JW modifier usage risks underpayment.
CMS confirmed this requirement in its 2023 Final Rule (88 FR 78818). Incorrect modifier use can trigger automatic payment reduction without a formal denial.
3. Laterality Errors and LCD Conflicts
Billing RT or LT modifiers inconsistently with ICD-10 diagnosis codes — for example, coding H40.1130 (primary open-angle glaucoma, right eye, mild stage) while billing procedure for the left eye — results in either auto-denial or partial payment at discretion of the payer’s automated edit.
The Novitas Solutions LCD for glaucoma (L38393), for example, requires strict diagnosis-to-laterality alignment. Mismatches are caught silently.
Hard Denials vs. Silent Underpayments: Key Differences
| Revenue Risk Factor | Hard Denials | Silent Underpayments |
| Visibility | High — CARC/RARC codes issued | Low — claim shows as ‘Processed’ |
| Primary Trigger | Missing auth, eligibility errors, no referral | Modifier misuse, bundling edits, LCD conflicts |
| Financial Footprint | Immediate $0 payment; visible in AR | Slow revenue erosion; rarely flagged |
| Detection Method | Standard denial worklist | Requires payer allowable vs. paid analytics |
| 2026 Trend | Stabilizing due to front-end scrubbing tools | Accelerating — MACs expanding automated edits |
| Appeal Pathway | Standard redetermination request | Formal overpayment dispute + contract review |
What This Means for Your Revenue in Real Numbers
Consider a mid-size ophthalmology practice performing 180 injection visits per month. If modifier -25 is being auto-reduced by $35 per encounter across two major payers, that is $6,300 per month — $75,600 annually — in silent revenue loss. No denial. No rework flag. Just a processed claim at a lower rate.
Our analysis across ophthalmology clients shows that practices without a dedicated revenue integrity partner carry an average of $62,000–$95,000 annually in undetected underpayments, most concentrated in diagnostic bundling and modifier disputes.
This is not a billing error problem. It is a monitoring infrastructure problem. Most internal billing teams are structured to work denial queues — not to run systematic payer allowable comparisons by CPT and modifier across every remittance.
Three Operational Fixes That Recover Silent Revenue
1. Monthly Payer Allowable Audits
Compare what each payer paid against your fee schedule allowable for the top 15–20 CPT codes in your practice. Flag any CPT where the average paid rate is more than 3% below the contracted rate. This catches systematic underpayment patterns before they compound.
2. Remittance Analytics by Modifier
Filter your EOBs to isolate claims billed with modifier -25, -59, -24, or -79. Run the paid rate for each. If modifier -25 claims are consistently paying at a lower rate than expected, you have a payer-side bundling edit targeting your practice.
3. LCD and Coverage Determination Monitoring
MACs update Local Coverage Determinations regularly. The Novitas Solutions and CGS Administrators LCDs for ophthalmology services — including fundus photography (CPT 92250), OCT (92134), and visual field testing (92083) — have seen policy updates in 2024–2025.
Practices using professional ophthalmology billing services stay current with these changes automatically. Those relying on generalist teams often miss policy shifts until claims start paying at reduced rates.
The Right Infrastructure Makes the Difference
Catching silent underpayments is not a one-time audit task — it is an ongoing operational discipline. Practices that partner with specialized medical billing and coding services built for eye care create a systematic layer of protection that generic billing vendors cannot replicate.
Effective rcm services for ophthalmology must include payer contract analytics, modifier-specific remittance tracking, and real-time LCD monitoring — not just claim submission and denial rework. The distinction between these two service levels is exactly where silent revenue loss accumulates.
If your practice has not reviewed its payer allowable performance in the last 90 days, you likely have undetected underpayments in your AR. Reviewing our can help you identify the right level of revenue protection for your practice volume and payer mix.
Stop Losing Revenue to Underpayments You Cannot See
Denials in ophthalmology billing are only part of the problem. The silent revenue loss hiding inside your ‘processed’ claims is the bigger threat in 2026.
Our team specializes in uncovering what your standard denial reports miss — payer allowable gaps, modifier-specific underpayments, and LCD compliance failures that quietly erode your net collection ratio.
Request a 90-Day Ophthalmology Revenue Integrity Review and find out exactly where your practice is losing money — before it compounds further.
Phone: 888-357-3226
Email: info@medicalbillersandcoders.com
FAQs: Denials in Ophthalmology Billing
A silent underpayment occurs when a payer marks a claim as ‘processed’ but pays below the contracted rate — often by auto-bundling diagnostic tests or downgrading modifiers — without issuing a formal denial code.
Run a monthly comparison of your payer’s allowed amount versus what was actually paid, filtered by CPT code and modifier. Consistent gaps of more than 3–5% on specific codes indicate systematic underpayment.
Yes, for Medicare patients. CMS mandated the JZ modifier on single-dose vial claims with zero drug waste effective January 1, 2023. Failure to include it can result in reduced or delayed reimbursement.
Hard denials are stabilizing as front-end verification improves, but silent underpayments are increasing due to expanded automated payer edits, stricter LCD enforcement, and modifier bundling logic applied by Medicare Advantage plans.
Yes. You can submit a formal redetermination or payer dispute citing the contracted fee schedule and the Medicare Claims Processing Manual (Chapter 12) as applicable. Document the discrepancy between your allowable and what was paid as the basis for the appeal.
With almost 12 years of experience in healthcare revenue cycle management, this Revenue Cycle Specialist brings deep expertise in medical billing, claims optimization, and practice profitability. Shares industry-backed insights focused on improving collections, reducing denials, and driving operational excellence.
